(Corrected at 9:51 pm: Dorte Klokker was misquoted pertaining to the costs that the pharmaceutical industry bears for a patient receiving treatments during trials as opposed to standard care. The quote now reads: "We bear a lot of costs when it comes to working hours, drugs and scanning." MedWatch apologizes for the mistake.)
Faster approvals, uniform legal contracts and more professional setups for clinical research units.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.